Body habitus changes related to lipodystrophy

Area of Science:

• Endocrinology
• Infectious Diseases
• Metabolic Syndrome

Background:

• Body fat changes in human immunodeficiency virus (HIV) patients are linked to adverse blood lipid profiles and insulin resistance.
• These metabolic alterations raise concerns about increased risk for accelerated atherosclerosis.
• Fat distribution changes can manifest early or late in HIV disease progression.

Purpose of the Study:

• To review the associations between HIV infection, body fat changes, and cardiovascular risk.
• To explore potential etiologies of fat maldistribution, including antiretroviral therapies.
• To discuss current and potential management strategies for body fat alterations in HIV-infected individuals.

Main Methods:

• Literature review of studies investigating body composition changes in HIV patients.
• Analysis of evidence regarding the role of protease inhibitors and nonnucleoside reverse transcriptase inhibitors in fat maldistribution.
• Evaluation of interventions for fat loss and fat accumulation.

Main Results:

• Conflicting evidence exists regarding the specific antiretroviral drugs causing fat maldistribution.
• Discontinuation of stavudine or zidovudine may partially restore extremity fat.
• Dietary changes (low saturated fat, low-glycemic index, high fiber) and exercise are recommended, mirroring general population guidelines.

Conclusions:

• The etiologies of body fat changes in HIV remain uncertain, with potential links to antiretroviral therapy.
• Management strategies should focus on lifestyle modifications, particularly diet and exercise, to address central obesity, dyslipidemia, and insulin resistance.
• Further research is needed to establish effective treatments for body fat alterations in HIV-infected individuals.